[go: up one dir, main page]

DK3060256T3 - Hidtil ukendt stabil formulering - Google Patents

Hidtil ukendt stabil formulering Download PDF

Info

Publication number
DK3060256T3
DK3060256T3 DK14786915.0T DK14786915T DK3060256T3 DK 3060256 T3 DK3060256 T3 DK 3060256T3 DK 14786915 T DK14786915 T DK 14786915T DK 3060256 T3 DK3060256 T3 DK 3060256T3
Authority
DK
Denmark
Prior art keywords
stable formulation
unknown
unknown stable
formulation
stable
Prior art date
Application number
DK14786915.0T
Other languages
English (en)
Inventor
Carsten Olbrich
Thomas Trill
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Application granted granted Critical
Publication of DK3060256T3 publication Critical patent/DK3060256T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68033Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK14786915.0T 2013-10-25 2014-10-21 Hidtil ukendt stabil formulering DK3060256T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13190276 2013-10-25
PCT/EP2014/072558 WO2015059147A1 (en) 2013-10-25 2014-10-21 A novel stable formulation

Publications (1)

Publication Number Publication Date
DK3060256T3 true DK3060256T3 (da) 2019-07-29

Family

ID=49552164

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14786915.0T DK3060256T3 (da) 2013-10-25 2014-10-21 Hidtil ukendt stabil formulering

Country Status (15)

Country Link
US (2) US20160250349A1 (da)
EP (1) EP3060256B1 (da)
JP (1) JP6813355B2 (da)
CY (1) CY1121791T1 (da)
DK (1) DK3060256T3 (da)
ES (1) ES2735645T3 (da)
HR (1) HRP20191053T1 (da)
HU (1) HUE045020T2 (da)
LT (1) LT3060256T (da)
PL (1) PL3060256T3 (da)
PT (1) PT3060256T (da)
RS (1) RS58856B1 (da)
SI (1) SI3060256T1 (da)
TR (1) TR201909034T4 (da)
WO (1) WO2015059147A1 (da)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32560A (es) 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
BR112019014785A2 (pt) * 2017-01-19 2020-05-12 Bayer Pharma Aktiengesellschaft Nova formulação estável para anticorpos fxia
WO2019039483A1 (ja) 2017-08-23 2019-02-28 第一三共株式会社 抗体-薬物コンジュゲートの製剤及びその凍結乾燥方法
WO2020234114A1 (en) 2019-05-21 2020-11-26 Bayer Aktiengesellschaft A novel stable high concentration formulation for anetumab ravtansine
CN119630433A (zh) 2022-05-23 2025-03-14 逻辑生物治疗公司 基因疗法组合物及其使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2281577B1 (en) * 2003-05-14 2016-11-16 ImmunoGen, Inc. Drug conjugate composition
WO2007019232A2 (en) * 2005-08-03 2007-02-15 Immunogen, Inc. Immunoconjugate formulations
TW200806315A (en) * 2006-04-26 2008-02-01 Wyeth Corp Novel formulations which stabilize and inhibit precipitation of immunogenic compositions
EP1854478A1 (en) * 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
UY32560A (es) * 2009-04-29 2010-11-30 Bayer Schering Pharma Ag Inmunoconjugados de antimesotelina y usos de los mismos
TWI582112B (zh) * 2011-04-21 2017-05-11 西雅圖遺傳學公司 新穎結合劑-藥物接合物(ADCs)及其用途(二)
JP6024025B2 (ja) * 2011-05-02 2016-11-09 イミューノメディクス、インコーポレイテッドImmunomedics, Inc. 少容量投与用のアロタイプ選択抗体の限外濾過濃縮
AU2012275233A1 (en) * 2011-06-30 2013-11-28 Genentech, Inc. Anti-c-met antibody formulations

Also Published As

Publication number Publication date
CY1121791T1 (el) 2020-07-31
HRP20191053T1 (hr) 2019-09-20
TR201909034T4 (tr) 2019-07-22
EP3060256B1 (en) 2019-05-08
LT3060256T (lt) 2019-07-10
SI3060256T1 (sl) 2019-08-30
WO2015059147A1 (en) 2015-04-30
RS58856B1 (sr) 2019-07-31
JP2016534062A (ja) 2016-11-04
US20190240345A1 (en) 2019-08-08
PL3060256T3 (pl) 2019-10-31
HUE045020T2 (hu) 2019-12-30
JP6813355B2 (ja) 2021-01-13
PT3060256T (pt) 2019-07-19
EP3060256A1 (en) 2016-08-31
ES2735645T3 (es) 2019-12-19
US20160250349A1 (en) 2016-09-01

Similar Documents

Publication Publication Date Title
HUE036179T2 (hu) Javított technikák felhasználói sík túlterheltség enyhítésére
EP3065716C0 (en) FORMULATIONS
PL3578266T3 (pl) Formulacja octanu abirateronu
EP3023769A4 (en) SPECTROSCOPE
DK3052080T3 (da) Langtidsvirkende spiro-isoxalin-formuleringer
DK2968214T3 (da) Hidtil ukendte analgetiske sammensætninger
EP2990093A4 (en) Dehumidifying device
HRP20182159T1 (hr) Poboljšane formulacije adenovirusa
IL246456A0 (en) Single vial vaccine formulations
SI3060229T1 (sl) Stabilne vodne formulacije protiteles
EP2968569A4 (en) COUGAR FORMULATION
EP2945195A4 (en) PHOTO DETECTOR
EP2957205A4 (en) HAND DRYER
EP2961397A4 (en) TRANSDERMAL FORMULATIONS
DK2887262T3 (da) Punktskyforenkling
DK2956010T4 (da) Fedtsammensætning
DK3060256T3 (da) Hidtil ukendt stabil formulering
DK3082762T3 (da) Langtidsvirkende ketoprofensammensætninger
CL2016001370A1 (es) Formulaciones de biomasa
DE102014221388B8 (de) Ladezustands-Berechungsvorrichtung
HUE050917T2 (hu) Hidrokortizon-tartalmú készítmény
EP2988734C0 (en) FORMULATION OF A HARD CAPSULE
DK2994136T3 (da) Nikotinpastilformulering
EP3064843A4 (en) Dehumidifier
HRP20180520T1 (hr) Suncobran